Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism.

Shulga N, Wilson-Smith R, Pastorino JG.

Cell Cycle. 2009 Oct 15;8(20):3355-64. Epub 2009 Oct 19.

2.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA.

Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.

3.

Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.

Wagner JM, Karnitz LM.

Mol Pharmacol. 2009 Jul;76(1):208-14. doi: 10.1124/mol.109.055178. Epub 2009 Apr 29.

4.

APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.

Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS.

Lung Cancer. 2009 Dec;66(3):298-304. doi: 10.1016/j.lungcan.2009.02.019. Epub 2009 Mar 25.

PMID:
19324449
5.

DNA-PKcs-PIDDosome: a nuclear caspase-2-activating complex with role in G2/M checkpoint maintenance.

Shi M, Vivian CJ, Lee KJ, Ge C, Morotomi-Yano K, Manzl C, Bock F, Sato S, Tomomori-Sato C, Zhu R, Haug JS, Swanson SK, Washburn MP, Chen DJ, Chen BP, Villunger A, Florens L, Du C.

Cell. 2009 Feb 6;136(3):508-20. doi: 10.1016/j.cell.2008.12.021. Retraction in: Cell. 2011 Apr 1;145(1):161.

6.

Platinum resistance: the role of DNA repair pathways.

Martin LP, Hamilton TC, Schilder RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238. Review.

7.

Resistance to therapy caused by intragenic deletion in BRCA2.

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A.

Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10.

PMID:
18264088
8.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T.

Nature. 2008 Feb 28;451(7182):1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.

9.

DNA repair pathways as targets for cancer therapy.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA.

Nat Rev Cancer. 2008 Mar;8(3):193-204. doi: 10.1038/nrc2342. Review.

PMID:
18256616
10.

ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.

Pabla N, Huang S, Mi QS, Daniel R, Dong Z.

J Biol Chem. 2008 Mar 7;283(10):6572-83. Epub 2007 Dec 27. Erratum in: J Biol Chem. 2008 May 30;283(22):15512.

11.

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA.

J Clin Oncol. 2007 Nov 20;25(33):5240-7.

PMID:
18024870
12.

The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM.

Annu Rev Pharmacol Toxicol. 2008;48:495-535. Review.

PMID:
17937596
13.

Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.

Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, Gerald WL, Powers S, Mu D.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8. Epub 2007 Oct 9.

14.

Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, Limmroth V, Thomale J.

J Neurosci. 2007 Aug 29;27(35):9451-7.

15.

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22. Epub 2007 Jul 11.

16.

The resurgence of platinum-based cancer chemotherapy.

Kelland L.

Nat Rev Cancer. 2007 Aug;7(8):573-84. Epub 2007 Jul 12. Review.

PMID:
17625587
17.

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.

Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW.

J Clin Invest. 2007 May;117(5):1370-80. Epub 2007 Apr 19.

18.

Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and pro-survival NF-kappaB pathway.

Tinel A, Janssens S, Lippens S, Cuenin S, Logette E, Jaccard B, Quadroni M, Tschopp J.

EMBO J. 2007 Jan 10;26(1):197-208. Epub 2006 Dec 7.

19.

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS.

Mol Cell Biol. 2006 Dec;26(24):9377-86. Epub 2006 Sep 25.

20.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators..

N Engl J Med. 2006 Sep 7;355(10):983-91.

Supplemental Content

Support Center